{
    "Trade/Device Name(s)": [
        "COBAS INTEGRA Glucose HK Gen. 3 Assay",
        "Glucose HK Gen. 3"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K092603",
    "Predicate Device Reference 510(k) Number(s)": [
        "K061048"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFR"
    ],
    "Summary Letter Date": "December 4, 2009",
    "Summary Letter Received Date": "November 5, 2009",
    "Submission Date": "November 3, 2009",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine",
        "Cerebrospinal fluid"
    ],
    "Specimen Container(s)": [
        "Li-heparin plasma tube",
        "K2-EDTA plasma tube",
        "K3-EDTA plasma tube",
        "Fluoride plasma tube"
    ],
    "Instrument(s)/Platform(s)": [
        "COBAS INTEGRA SYSTEMS",
        "COBAS INTEGRA 400",
        "COBAS INTEGRA 400 Plus",
        "COBAS INTEGRA 800"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic reference method",
        "Hexokinase"
    ],
    "Methodologies": [
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent system"
    ],
    "Document Summary": "FDA 510(k) summary for COBAS INTEGRA Glucose HK Gen. 3 enzymatic hexokinase assay for quantitation of glucose in serum, plasma, urine, and CSF",
    "Indications for Use Summary": "Quantitative measurement of glucose in serum, plasma, urine and cerebrospinal fluid to aid diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, idiopathic hypoglycemia, and pancreatic islet cell tumors",
    "fda_folder": "Clinical Chemistry"
}